Citations (241)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (47)
Woh Yon Mak,Jivanraj R. Nagarajah,Hannah Abdul Halim,Anitha Ramadas,Zulsairi Mohd Pauzi,Lay Ting Pee & Nirmala Jagan. (2020) Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital. Journal of Pharmaceutical Policy and Practice 13:1.
Read now
Read now
Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
Read now
Kathryn M. Hurren & Marissa W. Dunham. (2018) Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 19:10, pages 1087-1095.
Read now
Read now
Takashi Kadowaki, Satsuki Muto, Yoshiumi Ouchi, Ryutaro Shimazaki & Yutaka Seino. (2017) Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy 18:18, pages 1903-1919.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
Huan Yu & Vincent C Woo. (2017) Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin. Diabetes, Metabolic Syndrome and Obesity 10, pages 317-332.
Read now
Read now
Jayant Dey. (2017) SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus. Postgraduate Medicine 129:4, pages 409-420.
Read now
Read now
Lisa M. Younk, Elizabeth M. Lamos & Stephen N. Davis. (2016) Cardiovascular effects of anti-diabetes drugs. Expert Opinion on Drug Safety 15:9, pages 1239-1257.
Read now
Read now
Rose Anderson, Jennifer Hayes & Jeffrey W. Stephens. (2016) Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 467-473.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
Tamer Yacoub. (2016) Dapagliflozin combination therapy in type 2 diabetes mellitus. Postgraduate Medicine 128:1, pages 124-136.
Read now
Read now
Peter P Toth. (2015) Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular Health and Risk Management 11, pages 9-23.
Read now
Read now
Charles Andy Schuetz, Siew Hwa Ong & Matthias Blüher. (2015) Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. ClinicoEconomics and Outcomes Research 7, pages 313-323.
Read now
Read now
Shinya Nishio, Mariko Abe & Hiroyuki Ito. (2015) Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes, Metabolic Syndrome and Obesity 8, pages 163-171.
Read now
Read now
Wayne H.-H. Sheu, Sung Woo Park, Yan Gong, Sabine Pinnetti, Sudipta Bhattacharya, Sanjay Patel, Thomas Seck & Hans-Juergen Woerle. (2015) Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:3, pages 503-512.
Read now
Read now
Hiroyuki Konya, Yuzo Yano, Satoshi Matsutani, Taku Tsunoda, Takashi Ikawa, Yoshiki Kusunoki, Toshihiro Matsuo, Masayuki Miuchi, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-ichiro Miyagawa & Mitsuyoshi Namba. (2014) Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Therapeutics and Clinical Risk Management 10, pages 547-558.
Read now
Read now
William Cook, Gianmaria Minervini, Brian Bryzinski & Boaz Hirshberg. (2014) Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials. Postgraduate Medicine 126:6, pages 19-32.
Read now
Read now
Stanley Schwartz. (2014) Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine 126:3, pages 66-84.
Read now
Read now
Matthew L. Mintz & Gianmaria Minervini. (2014) Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current Medical Research and Opinion 30:5, pages 761-770.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
William Cook, Brian Bryzinski, Jill Slater, Robert Frederich & Elsie Allen. (2013) Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials. Postgraduate Medicine 125:3, pages 145-154.
Read now
Read now
Stephanie Aleskow Stein, Elizabeth Mary Lamos & Stephen N Davis. (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opinion on Drug Safety 12:2, pages 153-175.
Read now
Read now
Chetan S Karyekar, Shoba Ravichandran, Elsie Allen, Douglas Fleming & Robert Frederich. (2013) Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clinical Interventions in Aging 8, pages 419-430.
Read now
Read now
Shamsa Ali & Vivian Fonseca. (2013)
Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety 12:1, pages 103-109.
Read now
Read now
Michel P. Hermans, Tuncay Delibasi, Ian Farmer, Leif Lohm, Pierre Maheux, PierMarco Piatti, Elmas Malvolti, Silke Jörgens & Bernard Charbonnel. (2012) Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Current Medical Research and Opinion 28:10, pages 1635-1645.
Read now
Read now
Anthony H. Barnett, Bernard Charbonnel, Mark Donovan & Douglas Fleming. (2012) Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Current Medical Research and Opinion 28:4, pages 513-523.
Read now
Read now
Sherwyn L. Schwartz. (2012) Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies. Annals of Medicine 44:2, pages 157-169.
Read now
Read now
Thomas Forst & Andreas Pfützner. (2012) Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 13:1, pages 101-110.
Read now
Read now
Javier Morales. (2011) The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors. Postgraduate Medicine 123:6, pages 189-201.
Read now
Read now
Jean Doucet, Antonio Chacra, Pierre Maheux, Jane Lu, Susan Harris & Julio Rosenstock. (2011) Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Current Medical Research and Opinion 27:4, pages 863-869.
Read now
Read now
Paul S. Jellinger. (2011) Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 123:1, pages 53-65.
Read now
Read now
Pasquale J Palumbo & Jonathan M Wert. (2010) Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. Vascular Health and Risk Management 6, pages 17-26.
Read now
Read now
James E Foley & Jens Jordan. (2010) Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Vascular Health and Risk Management 6, pages 541-548.
Read now
Read now
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino & Jennifer B Green. (2010) Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, pages 7-19.
Read now
Read now
Morali D Sharma. (2010) Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Therapeutics and Clinical Risk Management 6, pages 233-237.
Read now
Read now
Baptist Gallwitz. (2010) New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 117-124.
Read now
Read now
Antonio R Chacra. (2010) Saxagliptin for type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 325-335.
Read now
Read now
Julio Rosenstock. (2010) Clinical overview of saxagliptin for Type 2 diabetes management. Expert Review of Endocrinology & Metabolism 5:6, pages 809-823.
Read now
Read now
Kaj Stenlöf, Itamar Raz, Joel Neutel, Shoba Ravichandran, Niklas Berglind & Roland Chen. (2010) Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Current Medical Research and Opinion 26:10, pages 2355-2363.
Read now
Read now
Marie T Brown & Derek LeRoith. (2010) Overcoming challenges in Type 2 diabetes management to improve patient outcomes. Expert Review of Endocrinology & Metabolism 5:5, pages 741-751.
Read now
Read now
Annie A. Mavian, Stephan Miller & Robert R. Henry. (2010) Managing Type 2 Diabetes: Balancing HbA1c and Body Weight. Postgraduate Medicine 122:3, pages 106-117.
Read now
Read now
Priscilla A. Hollander & Pamela Kushner. (2010) Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors. Postgraduate Medicine 122:3, pages 71-80.
Read now
Read now
Louis Kuritzky, Benjamin J. Epstein & Frank Lavernia. (2010) How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation. Postgraduate Medicine 122:3, pages 33-42.
Read now
Read now
Robert Frederich, John H. Alexander, Fred T. Fiedorek, Mark Donovan, Niklas Berglind, Susan Harris, Roland Chen, Robert Wolf & Kenneth W. Mahaffey. (2010) A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes. Postgraduate Medicine 122:3, pages 16-27.
Read now
Read now
Thomas Blevins. (2010) Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes. Postgraduate Medicine 122:1, pages 172-183.
Read now
Read now
Jay H Shubrook, Randall A Colucci & Frank L Schwartz. (2009) Exploration of the DPP-4 inhibitors with a focus on saxagliptin. Expert Opinion on Pharmacotherapy 10:17, pages 2927-2934.
Read now
Read now
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
Articles from other publishers (194)
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu & Hengjin Dong. (2022) Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:23, pages 7094.
Crossref
Crossref
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak & Linong Ji. (2022) Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. Frontiers in Endocrinology 13.
Crossref
Crossref
Shubo Jin, Wenyi Zhang, Yiwei Xiong, Sufei Jiang, Hui Qiao, Yongsheng Gong, Yan Wu & Hongtuo Fu. (2022) Genetic regulation of male sexual development in the oriental river prawn Macrobrachium nipponense during reproductive vs. non-reproductive season. Aquaculture International 30:4, pages 2059-2079.
Crossref
Crossref
Sharon Mackin and & Gemma Currie. 2022. Diabetes Drug Notes. Diabetes Drug Notes
67
94
.
Chirag Karshanbhai Patel, Disha Suthar, Hetal Patel, Vinit Movaliya & Punit Parejiya. (2022) Assessment of suitability of saxagliptin hydrochloride for development of controlled release parenteral formulation by preformulation studies. International journal of health sciences, pages 3223-3236.
Crossref
Crossref
Sunitha GURRALA, Shiva RAJ, Subrahmanyam CVS, Durga Panikumar ANUMOLU, Swathi NARAPARAJU & Harika NIZAMPET. (2022) Response Surface Methodology in Spectrophotometric Estimation of Saxagliptin, Derivatization with MBTH and Ninhydrin. Turkish Journal of Pharmaceutical Sciences 19:1, pages 9-18.
Crossref
Crossref
Bo Ahrén. (2021) Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition. Journal of Diabetes Investigation 12:7, pages 1128-1135.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Simin Zhang, Xueyao Han & Linong Ji. (2020) Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 37:3.
Crossref
Crossref
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim & Dae Jung Kim. (2021) Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea. Endocrinology and Metabolism 36:1, pages 70-80.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Sushrima GanAdem Y. Dawed, Louise A. DonnellyAnand T.N. NairColin N.A. PalmerViswanathan Mohan & Ewan R. Pearson. (2020) Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 43:8, pages 1948-1957.
Crossref
Crossref
Visnja Kokic Males. (2020) Letter to the editor in response to the article “COVID-19 and diabetes: Can DPP4 inhibition play a role?”. Diabetes Research and Clinical Practice 163, pages 108163.
Crossref
Crossref
Sayanta Thakur & Sandeep Lahiry. (2020) Multiplicity in clinical trial: An ignored concept. Indian Journal of Dermatology, Venereology and Leprology 86:2, pages 222.
Crossref
Crossref
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi Carlo Bottaro & Giorgio Lorenzo Colombo. (2020) Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Health Services Insights 13, pages 117863292092998.
Crossref
Crossref
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu & Koichiro Atsuda. (2019) Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan. Journal of Diabetes Investigation 11:1, pages 96-100.
Crossref
Crossref
Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah & Sheldon W. Tobe. (2019) Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 3:1.
Crossref
Crossref
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge Jabbour & Marcus Lind. (2019) Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care 42:8, pages 1464-1472.
Crossref
Crossref
Bo Ahrén. (2019) DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology 10.
Crossref
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Crossref
Y.K. Cho, Y.M. Kang, S.E. Lee, J. Lee, J.-Y. Park, W.J. Lee, Y.-J. Kim & C.H. Jung. (2018) Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes & Metabolism 44:5, pages 393-401.
Crossref
Crossref
Clement Lo, Tadashi Toyama, Ying Wang, Jin Lin, Yoichiro Hirakawa, Min Jun, Alan Cass, Carmel M Hawley, Helen Pilmore, Sunil V Badve, Vlado Perkovic & Sophia Zoungas. (2018) Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Peng Men, Xiao-tong Li, Hui-lin Tang & Suo-di Zhai. (2018) Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLOS ONE 13:5, pages e0197321.
Crossref
Crossref
Navneet Kumar Upadhyay, Charul Rathore, Sameer Sapra & Poonam Negi. (2018) NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SAXAGLIPTIN AND GLIMEPIRIDE. International Journal of Applied Pharmaceutics, pages 151-156.
Crossref
Crossref
Philip Home, R. Ravi Shankar, Ira Gantz, Carol Iredale, Edward A. O'Neill, Lokesh Jain, Annpey Pong, Shailaja Suryawanshi, Samuel S. Engel, Keith D. Kaufman & Eseng Lai. (2018) A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Research and Clinical Practice 138, pages 253-261.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas S. Denham, Prakash Prabhakar, Lise Kjems & Michelle A. Baron. (2018) Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes Care 41:3, pages 613-619.
Crossref
Crossref
Qing Ye & Jun-Fen Fu. (2018) Paediatric type 2 diabetes in China-Pandemic, progression, and potential solutions. Pediatric Diabetes 19:1, pages 27-35.
Crossref
Crossref
Guillermo E. Umpierrez, Timothy S. Bailey, Danielle Carcia, Charles Shaefer, Jay H. Shubrook & Neil Skolnik. (2018) Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. Journal of Diabetes 10:2, pages 94-111.
Crossref
Crossref
Alex Dmitrienko & Ralph B. D'AgostinoSr.Sr.. (2017) Editorial: Multiplicity issues in clinical trials. Statistics in Medicine 36:28, pages 4423-4426.
Crossref
Crossref
Beverley Balkau, Bernard Charbonnel, Alfred Penfornis, Nora Chraibi, Amir Lahouegue, Céline Faure, Florence Thomas-Delecourt & Bruno Detournay. (2017) The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study. Diabetes Therapy 8:5, pages 1147-1162.
Crossref
Crossref
Michael A. NauckJuris J. MeierMatthew A. CavenderMirna Abd El AzizDaniel J. Drucker. (2017) Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation 136:9, pages 849-870.
Crossref
Crossref
Mikaela Sjöstrand, Cheryl Wei, William Cook, Kristina Johnsson, Pia S. Pollack, Christina Stahre & Boaz Hirshberg. (2017) Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Therapy 8:3, pages 587-599.
Crossref
Crossref
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran. (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Ella Ekholm, Lars Hansen, Eva Johnsson, Nayyar Iqbal, Björn Carlsson, Hungta Chen & Boaz Hirshberg. (2017) COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. Endocrine Practice 23:3, pages 258-265.
Crossref
Crossref
Kayo Fujita, Masayuki Kaneko & Mamoru Narukawa. (2016) Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. Clinical Drug Investigation 37:3, pages 219-232.
Crossref
Crossref
Subodh Verma, Ronald M. Goldenberg, Deepak L. Bhatt, Michael E. Farkouh, Adrian Quan, Hwee Teoh, Kim A. Connelly, Lawrence A. Leiter & Jan O. Friedrich. (2017) Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open 5:1, pages E152-E177.
Crossref
Crossref
F. Barkas, M. Elisaf, V. Tsimihodimos & H. Milionis. (2017) Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. Diabetes & Metabolism 43:1, pages 1-8.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
David W. Boulton. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clinical Pharmacokinetics 56:1, pages 11-24.
Crossref
Crossref
. (2016) An update on the ‘gliptins’. Drug and Therapeutics Bulletin 54:12, pages 138-141.
Crossref
Crossref
Shira Perl, William Cook, Cheryl Wei, Peter Ohman & Boaz Hirshberg. (2016) Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Clinical Therapeutics 38:12, pages 2578-2588.
Crossref
Crossref
Xiaoyan Xiao, Xiaopei Cui, Jianbo Zhang, Zhenxia Han, Yu Xiao, Nan Chen, Baoying Li, Mei Cheng, Haiqing Gao & Kuanxiao Tang. (2016) Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study. Experimental and Therapeutic Medicine 12:5, pages 3002-3008.
Crossref
Crossref
Weiqiong Gu, Li. Liang, Shengxiang Wang, Yunzhi Wang, Yanxiang Wu, Jian Tian, Gangyi Yang, Chunli Piao, Yuzhong Li, Jianmei Yin, Xiaoping Xin, Xingrong Tan, Guang Ning & Weiqing Wang. (2016) Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. Journal of Diabetes 8:6, pages 809-815.
Crossref
Crossref
Feng-fei Li, Lan-lan Jiang, Reng-na Yan, Hong-hong Zhu, Pei-hua Zhou, Dan-feng Zhang, Xiao-fei Su, Jin-dan Wu, Lei Ye & Jian-hua Ma. (2016) Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes. Medicine 95:43, pages e5229.
Crossref
Crossref
Shira Perl, William Cook, Cheryl Wei, Nayyar Iqbal & Boaz Hirshberg. (2016) Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Therapy 7:3, pages 527-535.
Crossref
Crossref
Helena M. de Wit, Maarten te Groen, Maroeska M. Rovers & Cees J. Tack. (2016)
The placebo response of injectable GLP-1 receptor agonists
vs
. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
. British Journal of Clinical Pharmacology 82:1, pages 301-314.
Crossref
Crossref
S. Hong, C.‐Y. Park, K. A. Han, C. H. Chung, B. J. Ku, H. C. Jang, C. W. Ahn, M.‐K. Lee, M. K. Moon, H. S. Son, C. B. Lee, Y.‐W. Cho & S.‐W. Park. (2016)
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in
K
orean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase
III
trial
. Diabetes, Obesity and Metabolism 18:5, pages 528-532.
Crossref
Crossref
E. Bonora, B. Bryzinski, B. Hirshberg & W. Cook. (2016) A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutrition, Metabolism and Cardiovascular Diseases 26:5, pages 374-379.
Crossref
Crossref
J. Kongwatcharapong, P. Dilokthornsakul, S. Nathisuwan, A. Phrommintikul & N. Chaiyakunapruk. (2016) Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. International Journal of Cardiology 211, pages 88-95.
Crossref
Crossref
Bo Ahrén & James E. Foley. (2016) Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59:5, pages 907-917.
Crossref
Crossref
Wenjia Yang, Xiaoling Cai, Xueyao Han & Linong Ji. (2016) DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews 32:4, pages 391-404.
Crossref
Crossref
Hui WangXiufei LiuMin LongYi HuangLinlin ZhangRui ZhangYi ZhengXiaoyu LiaoYuren WangQian LiaoWenjie LiZili TangQiang TongXiaocui WangFang FangMontserrat Rojo de la VegaQin OuyangDonna D. ZhangShicang YuHongting Zheng. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine 8:334.
Crossref
Crossref
R. Buzzetti, P. Pozzilli, R. Frederich, N. Iqbal & B. Hirshberg. (2016) Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes/Metabolism Research and Reviews 32:3, pages 289-296.
Crossref
Crossref
Sung-Ho KimJung-Hwa YooWoo Je LeeCheol-Young Park. (2016) Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 40:5, pages 339.
Crossref
Crossref
Deborah Hinnen. (2015) Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. The Diabetes Educator 41:1_suppl, pages 19S-31S.
Crossref
Crossref
Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal & Lars Hansen. (2015) Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care 38:11, pages 2018-2024.
Crossref
Crossref
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen & Nayyar Iqbal. (2015) Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care 38:11, pages 2009-2017.
Crossref
Crossref
Rajeev Jain. (2015) Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Advances in Therapy 32:11, pages 1065-1084.
Crossref
Crossref
Rogier Wvan der Zanden, Frank de Vries, Arief Lalmohamed, Johanna H. M. Driessen, Anthonius de Boer, Gernot Rohde, Cees Neef & Casper den Heijer. (2015) Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLOS ONE 10:10, pages e0139367.
Crossref
Crossref
Sohita Dhillon. (2015) Saxagliptin: A Review in Type 2 Diabetes. Drugs 75:15, pages 1783-1796.
Crossref
Crossref
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber & Gislaine Tezza Rezin. (2015) Incretin-based therapies for obesity treatment. Metabolism 64:9, pages 967-981.
Crossref
Crossref
M. D. Sharma. (2015) Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 17:7, pages 616-621.
Crossref
Crossref
Linda Tran, Angela Zielinski, Arpi H. Roach, Jennifer A. Jende, Ann Marie Householder, Emily E. Cole, Shuruq A. Atway, Melinda Amornyard, Mallory L. Accursi, Suzanna W. Shieh & Erin E. Thompson. (2015) Pharmacologic Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 49:5, pages 540-556.
Crossref
Crossref
M. E. Rotz, V. S. Ganetsky, S. Sen & T. F. Thomas. (2015) Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 69:5, pages 531-549.
Crossref
Crossref
Xiaoling Cai, Xueyao Han, Yingying Luo & Linong Ji. (2014)
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on
β
‐cell function in
A
sian and
C
aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对
β
细胞功能的影响：一项meta分析
. Journal of Diabetes 7:3, pages 347-359.
Crossref
Crossref
Kristy M. Heppner & Diego Perez-Tilve. (2015) GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Frontiers in Neuroscience 9.
Crossref
Crossref
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg & Nayyar Iqbal. (2015) Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin. Diabetes Care 38:3, pages 376-383.
Crossref
Crossref
Nwe Ni Than & Philip N. Newsome. (2015) A concise review of non-alcoholic fatty liver disease. Atherosclerosis 239:1, pages 192-202.
Crossref
Crossref
Hae Kyung Yang, Kyung Wan Min, Sung Woo Park, Choon Hee Chung, Kyong Soo Park, Sung Hee Choi, Ki-Ho Song, Doo-Man Kim, Moon-Kyu Lee, Yeon-Ah Sung, Sei Hyun Baik, In Joo Kim, Bong-Soo Cha, Jeong Hyun Park, Yu Bae Ahn, In-Kyu Lee, Soon Jib Yoo, Jaetaek Kim, Ie Byung Park, Tae Sun Park & Kun-Ho Yoon. (2015) A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. Endocrine Journal 62:5, pages 449-462.
Crossref
Crossref
Wenjun WuYing LiXiong ChenDini LinSongying XiangFeixia ShenXuemei Gu. (2015) Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Medical Science Monitor 21, pages 2678-2684.
Crossref
Crossref
Joshua J. Neumiller. (2015) Incretin-Based Therapies. Medical Clinics of North America 99:1, pages 107-129.
Crossref
Crossref
Wenying Yang & Jianping Weng. (2014) Early therapy for type 2 diabetes in China. The Lancet Diabetes & Endocrinology 2:12, pages 992-1002.
Crossref
Crossref
K. M. Prasanna Kumar, Sunil M. Jain, Conrad Tou & Kajs-Marie Schützer. (2014) Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. International Journal of Diabetes in Developing Countries 34:4, pages 201-209.
Crossref
Crossref
Lars Hansen, Nayyar Iqbal, Ella Ekholm, William Cook & Boaz Hirshberg. (2014) Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy. Endocrine Practice 20:11, pages 1187-1197.
Crossref
Crossref
Brian Bryzinski, Elsie Allen, William Cook & Boaz Hirshberg. (2014) Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. Journal of Diabetes and its Complications 28:6, pages 887-893.
Crossref
Crossref
Anders Gummesson, Haiyan Li, Michael Gillen, John Xu, Mohammad Niazi & Boaz Hirshberg. (2014) Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. Clinical Drug Investigation 34:11, pages 763-772.
Crossref
Crossref
George Grunberger. (2014) Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology 70:11, pages 1277-1289.
Crossref
Crossref
Joshua J. Neumiller. (2014) Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes. Clinical Diabetes 32:4, pages 170-177.
Crossref
Crossref
Boaz Hirshberg, Artist Parker, Helen Edelberg, Mark Donovan & Nayyar Iqbal. (2014) Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews 30:7, pages 556-569.
Crossref
Crossref
Shiying Wu, Ingrid Hopper, Marina Skiba & Henry Krum. (2014) Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovascular Therapeutics 32:4, pages 147-158.
Crossref
Crossref
Mikaela Sjöstrand, Nayyar Iqbal, Jane Lu & Boaz Hirshberg. (2014) Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. Diabetes Research and Clinical Practice 105:2, pages 185-191.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 24:7, pages 689-697.
Crossref
Crossref
Shikhar Agarwal, Akhil Parashar & Venu Menon. (2014) Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. American Journal of Cardiovascular Drugs 14:3, pages 191-207.
Crossref
Crossref
Paul Craddy, Hannah-Jayne Palin & K. Ian Johnson. (2014) Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy 5:1, pages 1-41.
Crossref
Crossref
Jay H. ShubrookJrJr. (2014) Managing Recent-Onset Diabetes: Choosing Durable, Well-Tolerated Therapies and Understanding the Role of Incretin-Based Therapies. Journal of Osteopathic Medicine 114:s52, pages 6-13.
Crossref
Crossref
R. G. Moses, S. Kalra, D. Brook, J. Sockler, J. Monyak, J. Visvanathan, M. Montanaro & S. A. Fisher. (2014) A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes, Obesity and Metabolism 16:5, pages 443-450.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Lily P. H. Yang. (2014) Saxagliptin: a guide to its use in type 2 diabetes mellitus. Drugs & Therapy Perspectives 30:3, pages 92-99.
Crossref
Crossref
Jizhe Dong, Yanchun Gong, Jun Liu, Xiangfeng Chen, Xiaoan Wen & Hongbin Sun. (2014) Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. Bioorganic & Medicinal Chemistry 22:4, pages 1383-1393.
Crossref
Crossref
Kyong Yeun JungKyoung Min KimSoo Lim. (2014) Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. Diabetes & Metabolism Journal 38:6, pages 426.
Crossref
Crossref
Mansur Shomali. (2014) Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. Clinical Diabetes 32:1, pages 32-43.
Crossref
Crossref
Nayyar Iqbal, Artist Parker, Robert Frederich, Mark Donovan & Boaz Hirshberg. (2014) Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovascular Diabetology 13:1, pages 33.
Crossref
Crossref
X. Zhang, B. Brooks, L. Molyneaux, E. Landy, R. Banatwalla, T. Wu, J. Wong, B. Su & D. K. Yue. (2014) Dipeptidyl Peptidase-4 Inhibitors as a Third-Line Oral Antihyperglycaemic Agent in Patients with Type 2 Diabetes Mellitus: The Impact of Ethnicity. International Journal of Endocrinology 2014, pages 1-5.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:1, pages 48-56.
Crossref
Crossref
D. Wu, L. Li & C. Liu. (2014) Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, Obesity and Metabolism 16:1, pages 30-37.
Crossref
Crossref
J. Rosenstock, J. L. Gross, C. Aguilar-Salinas, M. Hissa, N. Berglind, S. Ravichandran & D. Fleming. (2013) Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabetic Medicine 30:12, pages 1472-1476.
Crossref
Crossref
Jaime A. Davidson. (2013) The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 19:6, pages 1050-1061.
Crossref
Crossref
Margaret C. Lo & M. Cecilia Lansang. (2013) Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus. American Journal of Therapeutics 20:6, pages 638-653.
Crossref
Crossref
S. Mudaliar. (2013) Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes. International Journal of Clinical Practice 67:9, pages 876-887.
Crossref
Crossref
George Grunberger. (2013) Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物). Journal of Diabetes 5:3, pages 241-253.
Crossref
Crossref
C. S. Karyekar, R. Frederich & S. Ravichandran. (2013)
Clinically relevant reductions in HbA
1c
without hypoglycaemia: results across four studies of saxagliptin
. International Journal of Clinical Practice 67:8, pages 759-767.
Crossref
Crossref
Anthony H. Barnett. (2013) Complementing Insulin Therapy to Achieve Glycemic Control. Advances in Therapy 30:6, pages 557-576.
Crossref
Crossref
Dara L. Eckerle Mize & Marzieh Salehi. (2013) The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists. Current Diabetes Reports 13:3, pages 307-318.
Crossref
Crossref
S. J. Yang, K. W. Min, S. K. Gupta, J. Y. Park, V. K. Shivane, S. U. Pitale, P. K. Agarwal, A. Sosale, P. Gandhi, M. Dharmalingam, V. Mohan, U. Mahesh, D. M. Kim, Y. S. Kim, J. A. Kim, P. K. Kim & S. H. Baik. (2013) A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 15:5, pages 410-416.
Crossref
Crossref
Cassie L Boland, Michelle DeGeeter, Donald S Nuzum & Maria Tzefos. (2013) Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors. Annals of Pharmacotherapy 47:4, pages 490-505.
Crossref
Crossref
Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist & Ingrid Gause-Nilsson. (2013) Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. International Journal of Clinical Practice 67:4, pages 307-316.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, S. H. Kwak, K. S. Park & Y. M. Cho. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:4, pages 696-708.
Crossref
Crossref
Abdul Halim Abdul Gafor, Azrina Abdul Kadir, Rizna Abdul Cader, Rozita Mohd, Kong Wei Yen, Rohana Abdul Ghani, Shamsul Azhar Shah & Norella C. T. Kong. (2013) The Efficacy and Safety of Saxagliptin in Haemodialysis Patients. Open Journal of Nephrology 03:02, pages 83-88.
Crossref
Crossref
Robert R. Henry. (2013) Antihyperglycemic Drug Therapy in Patients with Diabetes and Ckd: a Closer Look at Incretin-Based Therapies. Endocrine Practice 19, pages 19-22.
Crossref
Crossref
Nam Hoon KimSin Gon Kim. (2013) Comparison of DPP-4 Inhibitors. The Journal of Korean Diabetes 14:3, pages 111.
Crossref
Crossref
H Naik, J Lu, C Cao, M Pfister, M Vakilynejad & E Leifke. (2013) Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK‐875 in Subjects With Type 2 Diabetes Mellitus. CPT: Pharmacometrics & Systems Pharmacology 2:1, pages 1-10.
Crossref
Crossref
Michael Cobble. (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming & Roland Chen. (2012) The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
A. H. Barnett, S. Patel, R. Harper, R. Toorawa, S. Thiemann, M. von Eynatten & H.‐J. Woerle. (2012)
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase
III
trial with a 34‐week active‐controlled extension
. Diabetes, Obesity and Metabolism 14:12, pages 1145-1154.
Crossref
Crossref
Haesuk Park, Chanhyun Park, Yoona Kim & Karen L Rascati. (2012) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis. Annals of Pharmacotherapy 46:11, pages 1453-1469.
Crossref
Crossref
S. M. Poucher, S. Cheetham, J. Francis, B. Zinker, M. Kirby & S. P. Vickers. (2012) Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β‐cell mass in a streptozotocin‐induced mouse model of type 2 diabetes. Diabetes, Obesity and Metabolism 14:10, pages 918-926.
Crossref
Crossref
S. Cornell. (2012) Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 37:5, pages 510-524.
Crossref
Crossref
David Russell‐Jones & Stephen Gough. (2012) Recent advances in incretin‐based therapies. Clinical Endocrinology 77:4, pages 489-499.
Crossref
Crossref
Haiyan Li, Li Yang, Conrad K.P. Tou, Chirag G. Patel & June Zhao. (2012) Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects. Clinical Drug Investigation 32:7, pages 465-473.
Crossref
Crossref
K. R. Gerrald, E. Van Scoyoc, R. C. Wines, T. Runge & D. E. Jonas. (2011) Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:6, pages 481-492.
Crossref
Crossref
Vanita R. Aroda, Robert R. Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow & Byron J. Hoogwerf. (2012) Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 34:6, pages 1247-1258.e22.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil. Revista da Associação Médica Brasileira 58:3, pages 294-301.
Crossref
Crossref
Yook-Hwan Noh, Hyeong-Seok Lim, Seok-Joon Jin, Mi Jo Kim, Yo Han Kim, Hye Ryoung Sung, Hee Youn Choi & Kyun-Seop Bae. (2012) Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug–Drug Interaction Study in Healthy Male Korean Volunteers. Clinical Therapeutics 34:5, pages 1182-1194.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Revista da Associação Médica Brasileira (English Edition) 58:3, pages 294-301.
Crossref
Crossref
Marcelo Eidi Nita, Freddy G. Eliaschewitz, Eliane Ribeiro, Elio Asano, Elias Barbosa, Maíra Takemoto, Bonnie Donato, Roberto Rached & Elaine Rahal. (2012) Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Revista da Associação Médica Brasileira 58:3, pages 294-301.
Crossref
Crossref
V. Fonseca, T. Zhu, C. Karyekar & B. Hirshberg. (2012) Adding saxagliptin to extended‐release metformin vs. uptitrating metformin dosage. Diabetes, Obesity and Metabolism 14:4, pages 365-371.
Crossref
Crossref
Hélène Duez, Bertrand Cariou & Bart Staels. (2012) DPP-4 inhibitors in the treatment of type 2 diabetes. Biochemical Pharmacology 83:7, pages 823-832.
Crossref
Crossref
Anthony H. STONEHOUSE, Tamara DARSOW & David G. MAGGS. (2012) Incretin-based therapies. Journal of Diabetes 4:1, pages 55-67.
Crossref
Crossref
Chang Yu Pan, Wenying Yang, Conrad Tou, Ingrid Gause‐Nilsson & June Zhao. (2012) Efficacy and safety of saxagliptin in drug‐naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes/Metabolism Research and Reviews 28:3, pages 268-275.
Crossref
Crossref
R. E. van Genugten, D. H. van Raalte & M. Diamant. (2011) Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence. Diabetes, Obesity and Metabolism 14:2, pages 101-111.
Crossref
Crossref
Amir Hanna, Vincent Woo, Jean-François Yale & Elaine M. Cooke. (2012) Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. Canadian Journal of Diabetes 36:1, pages 9-14.
Crossref
Crossref
Lily P.H. Yang. (2012) Saxagliptin. Drugs 72:2, pages 229-248.
Crossref
Crossref
Michael E Cobble & Robert Frederich. (2012) Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovascular Diabetology 11:1, pages 6.
Crossref
Crossref
William T. Cefalu. (2012) Evolving Treatment Strategies for the Management of Type 2 Diabetes. The American Journal of the Medical Sciences 343:1, pages 21-26.
Crossref
Crossref
Wladyslaw GrzeszczakLeszek CzupryniakKatarzyna KolasaCezary SciborskiIsabelle Duprat LomonPhil McEwan. (2012) The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. Diabetes Technology & Therapeutics 14:1, pages 65-73.
Crossref
Crossref
. 2012. Churchill's Pocketbook of Diabetes. Churchill's Pocketbook of Diabetes
287
306
.
M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson & K-M. Schützer. (2011) Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. International Journal of Clinical Practice 65:12, pages 1230-1239.
Crossref
Crossref
F. Wilford Germino. (2011) Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A Review. Clinical Therapeutics 33:12, pages 1868-1882.
Crossref
Crossref
Ronald M. Goldenberg. (2011) Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents. Canadian Journal of Diabetes 35:5, pages 518-527.
Crossref
Crossref
D. R. Owens, R. Swallow, K. A. Dugi & H. J. Woerle. (2011) Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabetic Medicine 28:11, pages 1352-1361.
Crossref
Crossref
Wenying Yang, Chang Yu Pan, Conrad Tou, June Zhao & Ingrid Gause-Nilsson. (2011) Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Research and Clinical Practice 94:2, pages 217-224.
Crossref
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Crossref
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Ph. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Deborah L. Price, Roland Chen, Jacob Udell & Itamar Raz. (2011) The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal 162:5, pages 818-825.e6.
Crossref
Crossref
A. Chaudhuri & P. Dandona. (2011) Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism 13:10, pages 869-879.
Crossref
Crossref
R. R. Henry, S. R. Smith, S. L. Schwartz, S. R. Mudaliar, C. F. Deacon, J. J. Holst, R. Y. Duan, R. S. Chen & J. F. List. (2011) Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 13:9, pages 850-858.
Crossref
Crossref
Anthony H. Barnett & Jenny GriceAnthony H. Barnett & Jenny Grice. 2011. New Mechanisms in Glucose Control. New Mechanisms in Glucose Control
33
45
.
Deanna S. Kania, Jasmine D. Gonzalvo & Zachary A. Weber. (2011) Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:8, pages 1005-1022.
Crossref
Crossref
Roberta Baetta & Alberto Corsini. (2011) Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs 71:11, pages 1441-1467.
Crossref
Crossref
K. Esposito, D. Cozzolino, G. Bellastella, M. I. Maiorino, P. Chiodini, A. Ceriello & D. Giugliano. (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 13:7, pages 594-603.
Crossref
Crossref
Sindhu Akkati, Kishore Gnana Sam & Girish Tungha. (2011) Eemergence of Promising Therapies in Diabetes Mellitus. The Journal of Clinical Pharmacology 51:6, pages 796-804.
Crossref
Crossref
M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower & I. Gause-Nilsson. (2011) Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes, Obesity and Metabolism 13:6, pages 523-532.
Crossref
Crossref
M. Shawn McFarland, Meghan Brock & Casey Ryals. (2011) Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes. Southern Medical Journal 104:6, pages 426-439.
Crossref
Crossref
Karen R. Sando, Jose Barboza, Crystal Willis & James Taylor. (2011) Recent Diabetes Issues Affecting the Primary Care Clinician. Southern Medical Journal 104:6, pages 456-461.
Crossref
Crossref
Displaying 200 of 241 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list